Document is current
Any future updates will be listed below
-
Authors
Botta, Cirino https://orcid.org/0000-0002-1522-4504
Perez, Cristina https://orcid.org/0000-0003-3586-2666
Larrayoz, Marta https://orcid.org/0000-0001-6097-8244
Puig, Noemi
Cedena, Maria-Teresa https://orcid.org/0000-0001-5851-3720
Termini, Rosalinda
Goicoechea, Ibai https://orcid.org/0000-0002-5329-2225
Rodriguez, Sara https://orcid.org/0000-0001-6509-0447
Zabaleta, Aintzane
Lopez, Aitziber
Sarvide, Sarai
Blanco, Laura
Papetti, Daniele M. https://orcid.org/0000-0002-3574-6027
Nobile, Marco S. https://orcid.org/0000-0002-7692-7203
Besozzi, Daniela https://orcid.org/0000-0001-5532-3059
Gentile, Massimo
Correale, Pierpaolo
Siragusa, Sergio
Oriol, Albert
González-Garcia, Maria Esther
Sureda, Anna
de Arriba, Felipe
Rios Tamayo, Rafael https://orcid.org/0000-0001-8193-1402
Moraleda, Jose-Maria https://orcid.org/0000-0001-9080-1466
Gironella, Mercedes
Hernandez, Miguel T.
Bargay, Joan
Palomera, Luis
Pérez-Montaña, Albert
Goldschmidt, Hartmut https://orcid.org/0000-0003-0961-0035
Avet-Loiseau, Hervé
Roccaro, Aldo https://orcid.org/0000-0002-1872-5128
Orfao, Alberto https://orcid.org/0000-0002-0007-7230
Martinez-Lopez, Joaquin
Rosiñol, Laura https://orcid.org/0000-0002-2534-9239
Lahuerta, Juan-José https://orcid.org/0000-0002-3393-9570
Blade, Joan https://orcid.org/0000-0002-4563-3405
Mateos, Maria-Victoria https://orcid.org/0000-0003-2390-1218
San-Miguel, Jesús F. https://orcid.org/0000-0002-9183-4857
Martinez Climent, Jose-Angel https://orcid.org/0000-0002-7938-3950
Paiva, Bruno https://orcid.org/0000-0003-1977-3815
,
,
- License Information
-
More Information
Article History
Received: 25 November 2022
Accepted: 7 September 2023
First Online: 20 September 2023
Competing interests
: C.B. has served as a member on advisory boards for Amgen, Janssen, Pfizer, Takeda, and Oncopeptides; A.R. has received honoraria from Amgen, Celgene, and Janssen and a research grant from AstraZeneca and the Associazione Italiana per la Ricerca sul Cancro (AIRC): AIRC-IG-24689. H.G. has received speakers bureau honoraria from Academy2, KG, Agentur Hogg Robinson Germany, Amgen, ArtTempi, Beupdated Helbig Consulting and Research AG Schweiz, Bristol Myers Squibb, Celgene, Chop, Chugai, Congress Culture Concept Dr. S. Stocker München, Connectmedia Warschau/Polen, Dr. Hubmann Tumorzentrum München, FomF, GlaxoSmithKline, GWT Forschung und Innovation Dresden, Institut für Versorgungsforschung in der Onkologie GbR, Janssen, Kompetenznetz Maligne Lymphome, MedConcept, Medical Communication, Münchner Leukämie Labor Prof. Haferlach, New Concept Oncology, Novartis, Omnia Med Deutschland, Onko Internetportal DKG-web, Sanofi, STIL Forschungs, and Veranstaltungskonzept Gesundheit Mechernich, has served as a member on advisory boards for Adaptive Biotechnology, Amgen, Bristol Myers Squibb, Celgene, Janssen, Sanofi, and Takeda, and has received research grants and/or materials such as investigational medicinal products from Amgen, Bristol Myers Squibb, Celgene, Chugai, Dietmar-Hopp-Foundation, Janssen, John Hopkins University, and Sanofi. A. Oriol participated in advisory boards for Amgen, Celgene and Janssen. M.-V.M. has received honoraria for lectures from or participated in advisory boards for Janssen, Celgene, Amgen, Takeda, AbbVie, Adaptive, GSK, Pharmamar, EDO, and Oncopeptides. L.R. reports honoraria from Janssen, Celgene, Amgen, and Takeda. J.B. reports honoraria for lectures from Janssen, Amgen, Celgene, Takeda, and Oncopeptides. J.-J.L. reports honoraria from and membership on boards of directors or advisory committees with Takeda, Amgen, Celgene, and Janssen. J.F.S.-M. reports consultancy for Bristol-Myers Squibb, Celgene, Novartis, Takeda, Amgen, MSD, Janssen, and Sanofi and membership on a board of directors or advisory committee with Takeda. J.A.M.-C. has received research grants from Roche, Bristol-Myers Squibb-Celgene, and Janssen. B.P. reports honoraria for lectures from and membership on advisory boards with Adaptive, Amgen, Becton Dickinson, Bristol-Myers Squibb-Celgene, Janssen, Merck, Novartis, Roche, Sanofi and Takeda; unrestricted grants from Bristol-Myers Squibb-Celgene, EngMab, Roche, Sanofi, and Takeda; and consultancy for Bristol-Myers Squibb-Celgene, Janssen, Sanofi, and Takeda. The remaining authors declare no competing interests.
